SSS. S. Safronova

S. S. Safronova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


S. S. Safronova has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ФАКТОРЫ, АССОЦИИРОВАННЫЕ С ГИПЕРТРОФИЕЙ ЛЕВОГО ЖЕЛУДОЧКА У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА И ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ

    by И.в. Друк, С.с. Сафронова, О.и. Канунникова, О.ю. Кореннова, В.э. Смяловский, Е.а. Быкова, М.в. Новицкая

    Цель: изучить факторы, ассоциированные с формированием гипертрофии левого желудочка у пациентов с сахарным диабетом 2 типа и гипертонической болезнью. Результаты: проведен ретроспективный анализ медицинских данных амбулаторных карт пациентов с сахарным диабетом 2 типа и гипертонической болезнью на базе кафедры внутренних болезней и семейной медицины дополнительного профессионального образования Федерального государственного бюджетного образовательного учреждения высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации, бюджетного учреждения здравоохранения Омской области «Клинический кардиологический диспансер». В ходе анализа пациенты были разделены на две группы по результатам эхокардиогафии: наличие гипертрофии левого желудочка (группа 1, n=62) и ее отсутствие (группа 2; n=287). При сравнении групп: пациенты группы 1 имели более длительный анамнез сахарного диабета 2 типа и гипертонической болезни, более высокий показатель индекса коморбидности Чарлсона, большую распространенность микрососудистых осложнений сахарного диабета. В группе 1 пациенты реже достигали целевой уровень гликированного гемоглобина, чаще получали инсулинотерапию, имели более высокую степень артериальной гипертензии в дебюте гипертонической болезни, при наблюдении - более высокие уровни систолического артериального давления и пульсового давления, глюкозы плазмы натощак, гликированного гемоглобина. Шансы развития гипертрофии левого желудочка в изучаемой когорте были значимо выше при уровне глюкозы плазмы натощак >10,46 ммоль/л, гликированного гемоглобина >9,05%, при более высоких уровнях вариабельности HbA1c, значениях триглицеридно-глюкозного индекса 9,38-9,81, систолического артериального давления >140 мм рт. ст. и пульсового давления >54 мм рт. ст. Факторы, ассоциированные с гипертрофией левого желудочка: стаж артериальной гипертензии, гликированный гемоглобин при верификации диагноза сахарного диабета 2 типа, средний уровень глюкозы плазмы натощак, среднее систолическое артериальное давление.

  • Open Access

    Biomarkers of heart failure in patients with type 2 diabetes mellitus: clinical comparisons and impact of hypoglycemic therapy

    by I. V. Druk, S. S. Safronova, O. Yu. Korennova, O. I. Kanunnikova, A. S. Kazachenko

    The main cause of increased mortality in patients with type 2 diabetes mellitus (DM2) is heart failure (HF). HF leads to an increase in the number of hospitalizations, a deterioration in the quality of life and prognosis. As the incidence of HF in DM2 is constantly increasing, there is increased interest in optimal diagnostic and prognostic algorithms using a panel of circulating biomarkers to ensure timely diagnosis, improve disease treatment and patient prognosis. As the number of new HF biomarkers is growing rapidly, this review outlines the most promising and accessible biomarkers associated with fibrosis, a key pathophysiological mechanism of HF, and describes their usefulness for the diagnosis, risk stratification, and screening of HF in DM2, as well as existing limitations.

  • Open Access

    Gastroesophageal reflux disease, obesity, bronchial asthma: simple combination or complex interaction

    by I. V. Druk, E. V. Usacheva, E. V. Nadey, S. S. Safronova, N. A. Usachev

    Gastroesophageal reflux disease (GERD) continues to be one of the most common diseases in primary health care. In recent years, the presence of several diseases in the same patient at the same time has been widely discussed. An increase in persons suffering from several chronic diseases is associated with a deterioration in the quality of life, a high risk of hospitalization and mortality, and taking into account the presence of co/poly/multimorbidity is necessary for decision-making when developing a patient management strategy in primary health care. Studies on GERD, obesity and bronchial asthma have shown that there are common and bidirectional mechanisms in the development of these diseases. And, there are many gaps in understanding these relationships, it is important to identify concomitant diseases, since they can be the cause of resistance to therapy, to form an unfavorable prognosis of their course.


  • Open Access

    Obesity: current state of the problem, multidisciplinary approach. (based on the consensus of the World Gastroenterological Organization “Obesity 2023” and the European guideline on obesity care in patients with gastrointestinal and liver diseases, 2022)

    by M. A. Livzan, E. A. Lyalyukova, I. V. Druk, S. S. Safronova, A. A. Khalashte, K. A. Martirosian, V. Yu. Petrosian, Ya. S. Galakhov, В. Ю. Петросян

    Obesity is the largest pandemic in the world, and its prevalence continues to increase. The purpose of the presented publication is to raise awareness of doctors about modern methods of diagnosing obesity and approaches to therapy, using an interdisciplinary team approach similar to that used in other chronic diseases, such as diabetes, heart disease and cancer. The article presents data from the World Gastroenterological Organization (2023) and the European Guidelines for the Treatment of Obesity in patients with diseases of the gastrointestinal tract and liver (2022). According to modern approaches, obesity should be considered as a chronic recurrent progressive disease, the treatment of which requires a comprehensive interdisciplinary approach involving psychologists and psychiatrists, nutritionists/nutritionists, therapists, endoscopists and surgeons, including lifestyle changes, a well-defined diet and exercise regimen, drug therapy, endoscopic or surgical methods of treatment. Conclusions. In order to stop the growing wave of obesity and its many complications and costs, doctors, insurance companies and health authorities should make systematic efforts to raise public awareness of both the adverse health risks associated with obesity and the potential reduction of risks through a comprehensive approach to therapy.


  • Open Access

    Glycemic control and cardiovascular complications of type 2 diabetes mellitus

    by I. V. Druk, S. S. Safronova

    Over the past few decades, the prevalence of diabetes in developed and developing countries has increased dramatically, making diabetes a key health priority worldwide. It can be assumed that an increase in the life expectancy of patients with diabetes significantly affects the prevalence of diabetes, maintaining the trend of its increase. Patients with type 2 diabetes mellitus (DM2) are at higher risk for cardiovascular disease and its adverse outcomes compared to the general population. The pathophysiological relationship between hyperglycemia and cardiovascular disease is beyond doubt. Glycemic control per se remains essential for the successful management of diabetes, prevention of chronic complications of the disease and death. Diabetes control involves, first of all, the achievement of target indicators of carbohydrate metabolism. The use of glycated hemoglobin (HbA1c), despite known sensitivity limitations, has become the standard for assessing glycemic control in diabetic patients. Early achievement of the target HbA1c level reduces the risk of diabetic complications, increases the likelihood of long-term sustainable disease control. Numerous clinical studies have demonstrated that higher HbA1c and greater HbA1c variability are manageable risk factors for adverse cardiovascular events. Optimal hypoglycemic therapy for diabetes in order to reduce cardiovascular risks should ensure the achievement of the target level of glycemic control as soon as possible (the first 3 months of therapy), maintaining the target level of glycemia with the lowest possible HbA1c variability in subsequent years and therapy should be safe. Timely intensification of therapy, including the use of insulin, can prevent the negative consequences of prolonged hyperglycemia. Glar-100 has a high efficacy and safety in comparison with other insulin preparations at the initiation and intensification of DM2 therapy. RingGlar® and Lantus® are equivalent drugs.